TP53 and cancer: Restoration of wild-type p53 function has led to regression of cancers in mice [137, 138], and thus efforts to treat cancers through the reactivation of p53 with a low-molecular-weight compound such as PRIMA-1 (p53-dependent reactivation and induction of massive apoptosis) [139, 140] are widely supported.